Although mantle cell lymphoma is extremely radiosensitive, 75 percent not sufficient treatment MCL because of their systemic nature. The researchers presumed that by administering RIT after after 13-16 6 rounds 6 rounds chemotherapy, they could first reduce the tumor burden, then reach the systemic disease.
Theative approach to treating mantle cell lymphoma results in a high complete remission ratemantle cell lymphoma, a subtype of adult non-Hodgkin's lymphoma , which represents approximately 5 percent of NHL in the United States and Europe. Standard treatment of mantle cell lymphoma with chemotherapy poor results poor results in the promotion of survival, suggesting that new and innovative treatments are being explored. Doctors from Memorial Sloan - Kettering Cancer Center in New York City increased the clinical challenge and presented their findings at the Society of Nuclear Medicine 51st Annual Meeting.Notes:Other participants had Nashville research assistant Kathryn Lindler and Lynnette Daws, and Anthony Owens, of both of the University of Texas Health Science Center at San Antonio.
Blakely and his colleagues have earlier reports that inflammatory cytokines , the activities of the serotonin transporter like behavior. Improve the supply the neurotransmitter serotonin of the synapse , or gap between the nerve cell.